Skip to main page content

What's New in Uveitis

My Session Status

When:
3:45 PM, Friday 1 Jun 2018 (1 hour 30 minutes)
Theme:
Uveitis
LEARNING OBJECTIVES
At the end of this session, participants will be able to:
  • Assess new treatments for uveitis
  • Describe the use of HIV screening for patients with ocular syphilis
  • Integrate into their practice a first-visit questionnaire for uveitis

CANMEDS ROLES: Medical Expert, Scholar

Sub Sessions

3:45 PM - 3:50 PM | 5 minutes

Karin Oliver

Participant
3:50 PM - 4:02 PM | 12 minutes
First Prize, COS Awards of ExcellenceAward Winner

FIRST PRIZE, COS AWARDS FOR EXCELLENCE IN OPHTHALMIC RESEARCHAuthor: Jordan Isenberg Author Disclosure Block: J. Isenberg: None. Abstract Body: Purpose: Ocular toxoplasmosis (OT) is the most common etiology of posterior uveitis. The high incidence of macular scarring associated with OT is a leading cause of visual morbidity. Serum biomarkers of the disease would aid in its diagnosis. This study ...

4:02 PM - 4:22 PM | 20 minutes
Keynote Speaker
4:22 PM - 4:34 PM | 12 minutes

Authors: Andrei F. Dan, Christian El-Hadad, Eric Fortin, Karin Oliver Author Disclosure Block: A.F. Dan: Employment/honoraria/consulting fees; Name of Commercial Company(s); ZenXMed. C. El-Hadad: None. E. Fortin: Grant/research support; Name of Commercial Company(s); AbbVie,Allergan. Employment/honoraria/consulting fees; Name of Commercial Company(s); AbbVie, Allergan, Alcon/Novartis. K. Oliver: None. Abstract Body: Purpose: First-visit q...

Andrei F. Dan

Participant
4:34 PM - 4:46 PM | 12 minutes

Authors: Solin Saleh, Chris Welsh, Chloe Gottlieb Author Disclosure Block: S. Saleh: None. C. Welsh: None. C. Gottlieb: None. Abstract Body: Purpose: Ozurdex (Allergan, Inc, Irvine, California) is a sustained-release intravitreal dexamethasone implant that delivers corticosteroid directly to the posterior segment of the eye, allowing for controlled drug release over approximately 6 months. To date, few studies have been carried out to ass...

4:46 PM - 4:58 PM | 12 minutes

Authors: Zainab Khan, Julie Vadboncoeur, Yasmine Rabia, Bouchra Serhir, Annie-Claude Labbé, Claude Fortin, Kinda Najem, Laurence Jaworski, Marie-Josée Aubin Author Disclosure Block: Z. Khan: None. J. Vadboncoeur: None. Y. Rabia: None. B. Serhir: None. A. Labbé: None. C. Fortin: None. K. Najem: None. L. Jaworski: None. M. Aubin: Grant/research support; Name of Commercial Company(s); AbbVie. Employment/honoraria/consulting fees; Name of Commercial Company(s); Gilead. Membershi...

4:58 PM - 5:15 PM | 17 minutes

My Session Status

Send Feedback

Session detail
Allows attendees to send short textual feedback to the organizer for a session. This is only sent to the organizer and not the speakers.
To respect data privacy rules, this option only displays profiles of attendees who have chosen to share their profile information publicly.

Changes here will affect all session detail pages